Skip to content

Biohaven

US · BHVN #2805 by market cap Listed 2017
12.39 -1.26 -9.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Accumulating
  • Total institutional ownership rose 0.3 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
94.32% +0.29pp
Institutions
343
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund46.66%
Hedge Fund35.93%
Individual/Insider10.94%
Private Company4.00%
Public Company3.91%
VC/PE Fund2.00%
Insurance Company1.09%
Government Pension Fund0.43%
Family Office/Trust0.30%

Top holders as of 2026-09-30

BlackRock 8.57% · 12.95M sh
Montanova Capital, LLC 6.81% · 10.29M sh
Stifel Asset Management Corp. 6.58% · 9.94M sh
John Childs 6.54% · 9.88M sh
Janus Henderson Group plc 5.68% · 8.58M sh
Woodline Partners LP 5.07% · 7.66M sh
State Street Global Advisors 4.55% · 6.87M sh
Infinitum Asset Management, LLC 4.14% · 6.25M sh
D. E. Shaw & Co., L.P. 2.77% · 4.19M sh
AQR Capital Management 2.70% · 4.08M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 37 buys · 9 sells

NameRoleStake
John Childs Independent Director 6.54%
Vladimir Coric Chairperson & CEO 2.55%
Gregory Bailey Independent Director 1.34%
Warren Volles General Counsel & Chief Legal Officer 0.16%
Matthew Buten Chief Financial Officer 0.13%
Kimberly Gentile Senior Vice President of Clinical Operations 0.07%
George Clark Vice President 0.06%
Bruce Car Chief Innovation Officer 0.04%
Julia Gregory Independent Director 0.02%
Kishan Mehta Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-14 Kimberly Gentile Senior Vice President of Clinical Operations Other Derivative Acquisition +1,000 $12.34
2026-08-05 Infinitum Asset Management, LLC -- Initial Statement of Beneficial 0 --
2026-07-08 Warren Volles General Counsel & Chief Legal Officer Initial Statement of Beneficial 0 --
2026-04-27 John Childs Independent Director Other Derivative Acquisition +68,693 $9.61
2026-04-27 Julia Gregory Independent Director Other Derivative Acquisition +68,693 $9.61
2026-04-27 Robert Hugin Independent Director Other Derivative Acquisition +68,693 $9.61
2026-04-27 Gregory Bailey Independent Director Other Derivative Acquisition +68,693 $9.61
2026-04-27 Michael Heffernan Lead Independent Director Other Derivative Acquisition +68,693 $9.61
2026-04-27 Irina Antonijevic Independent Director Other Derivative Acquisition +68,693 $9.61
2026-04-27 Kishan Mehta Director Other Derivative Acquisition +68,693 $9.61
2026-03-16 Kishan Mehta Director Other Acquisition +17,342 --
2026-03-16 Kishan Mehta Director Other Disposition -17,342 --
2026-02-26 Matthew Buten Chief Financial Officer Other Derivative Acquisition +175,000 $11.52
2026-02-26 Vladimir Coric Chairperson & CEO Other Derivative Acquisition +550,000 $11.52
2026-02-26 Kimberly Gentile Senior Vice President of Clinical Operations Other Derivative Acquisition +175,000 $11.52
2026-02-26 Bruce Car Chief Innovation Officer Other Derivative Acquisition +175,000 $11.52
2026-02-26 George Clark Vice President Other Derivative Acquisition +50,000 $11.52
2026-01-04 Matthew Buten Chief Financial Officer Derivative Exercise and Sale -2,594 $9.93
2026-01-04 Matthew Buten Chief Financial Officer Derivative Exercise and Retained +1,656 --
2026-01-04 Vladimir Coric Chairperson & CEO Derivative Exercise and Sale -7,430 $9.93

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:17 · For reference only, not investment advice and not tailored to your situation.

Biohaven discussion 0 comments

Add a comment